Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Wei Sen Lam"'
Autor:
Brendan J. Crosby, Robert U. Newton, Daniel A. Galvão, Dennis R. Taaffe, Pedro Lopez, Tarek M. Meniawy, Muhammad A. Khattak, Wei‐Sen Lam, Elin S. Gray, Favil Singh
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14694-14706 (2023)
Abstract Purpose To determine the feasibility, safety and preliminary efficacy of a telehealth supervised exercise programme in patients with advanced melanoma receiving checkpoint inhibitor therapy. Methods A 8‐week non‐randomised feasibility pi
Externí odkaz:
https://doaj.org/article/49605488641649d1bf952aa39fa47199
Autor:
Chee Khoon Lee, M.B.B.S., PhD, Yu Yang Soon, MSc, Rosalind L. Jeffree, MSc, Rohit Joshi, MD, Eng-Siew Koh, M.B.B.S, Wei-Sen Lam, M.B.B.S., Hien Le, M.B.B.S., Zarnie Lwin, M.B.B.S., Mark B. Pinkham, MA (Hons), Shankar Siva, PhD, Evan Ng, M.B.B.S., Thomas John, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100553- (2023)
Life-prolonging central nervous system active systemic therapies for metastatic NSCLC have increased the complexity of managing brain metastases (BMs). Australian medical oncologists, radiation oncologists, and neurosurgeons discussed the evidence gu
Externí odkaz:
https://doaj.org/article/657d7ff6293e4261bc9af0a19b6e6fa0
Publikováno v:
BMJ case reports. 14(11)
We present a 65-year-old female smoker who presented with acute bilateral blurred vision. Investigations led to an endobronchial ultrasound-guided fine-needle aspiration resulting in an early diagnosis of limited stage small cell lung cancer. Positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db78df9314bfdca6c3c3fc8c47d9979
https://pubmed.ncbi.nlm.nih.gov/34764094
https://pubmed.ncbi.nlm.nih.gov/34764094
Autor:
Johnathan Soggee, Maddaleine Hunt, Barbara O'Callaghan, Wei‐Sen Lam, Paul Cannell, Glenn Boardman, Bruce Sunderland, Petra Czarniak
Publikováno v:
Asia-Pacific Journal of Clinical Oncology.
Prescription-related errors and misinterpretation of oral cancer treatment instructions can lead to significant harm or fatal outcomes for patients. The impact of specialist pharmacist-led consultation for patients taking oral antineoplastic medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73ee5ad09dbddcab53c31c21d37ec9a1
https://doi.org/10.1111/ajco.13887
https://doi.org/10.1111/ajco.13887
Autor:
Roy Herbst, Wei-Sen Lam, Matthew Hellmann, Matthew Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne Chiu, Jong-Seok Lee, James Chih-Hsin Yang, Edward Garon, Giovanna Finocchiaro, Myung-Ju Ahn, Alexander Luft, Gregory Landers, Andrea Basso, Hua Ma, Julie Kobie, John Palcza, Razvan Cristescu, Lawrence Fong, Alexandra Snyder, Jianda Yuan, Martin Gutierrez
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6914afa9aeac906b9e5e9ce6d58ce264
https://doi.org/10.1136/jitc-2022-sitc2022.0635
https://doi.org/10.1136/jitc-2022-sitc2022.0635
Publikováno v:
Endocrine-Related Cancer. 28:521-527
Thirty-seven patients with advanced gastroenteropancreatic neuroendocrine tumors (GEPNETs) were treated on a prospective phase II single-center study with four cycles of 7.8 GBq 177Lu-octreotate combined with capecitabine and temozolomide chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b571a54ac9516ff36837b9697d3144
https://doi.org/10.1530/erc-21-0082
https://doi.org/10.1530/erc-21-0082
Autor:
Deme Karikios, Connull Leslie, Peey-Sei Kok, Nick Pavlakis, Brett G.M. Hughes, Karen Briscoe, Sonia Yip, Alistair M. Cook, Steven Kao, Wei Sen Lam, W. Joost Lesterhuis, Anna K. Nowak, Kenneth J. O'Byrne, Ailsa Langford, Martin R. Stockler, Chris Brown, Thomas John, Christos S. Karapetis
Publikováno v:
The Lancet Oncology. 21:1213-1223
Summary Background There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7120ee0ef636d50a2c42de83272c0e9
https://doi.org/10.1016/s1470-2045(20)30462-9
https://doi.org/10.1016/s1470-2045(20)30462-9
Autor:
Michael Millward, Sanjeevan Muruganandan, Wei Sen Lam, J. Spiro, Sukanya Arunachalam, Aron Chakera, Y. C. Gary Lee, Catherine A. Read, Mary S. Attia, Anna K. Nowak, Fred K. Chen, Wee Loong Chin, Kevin Murray, Jenette Creaney
Publikováno v:
Lung Cancer. 140:87-92
Objectives Currently, there is no optimal salvage therapy for patients with malignant pleural mesothelioma (MPM) who relapse after treatment with first-line chemotherapy. In line with the strong preclinical rationale for targeting fibroblast growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ffd94933a545190c1c0dd9d34ce7dd
https://doi.org/10.1016/j.lungcan.2019.12.018
https://doi.org/10.1016/j.lungcan.2019.12.018
Autor:
Daniel Shao Weng Tan, Razvan Cristescu, Alexandra Snyder, Matthew A. Gubens, Lawrence Fong, Martin Gutierrez, Charu Aggarwal, Enriqueta Felip, Joanne Wy Chiu, Giovanna Finocchiaro, Myung-Ju Ahn, Hua Ma, Gregory Landers, John Palcza, Jianda Yuan, James Chih-Hsin Yang, Jong Seok Lee, J. Kobie, Andrea D. Basso, Edward B. Garon, Wei-Sen Lam, Matthew D. Hellmann, Alexander Luft, Roy S. Herbst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundT-cell–inflamed gene expression profile (TcellinfGEP) and tumor mutational burden (TMB) are clinically validated biomarkers that independently predict pembrolizumab response. This study investigated prospective TcellinfGEP and TMB assessm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542d982fddea3de177bde10798995c6f
https://doaj.org/article/f606c751f88546b2b65dd38f5eef52da
https://doaj.org/article/f606c751f88546b2b65dd38f5eef52da
Autor:
Michael Millward, Mary S. Attia, Sanjeevan Muruganandan, Fred K. Chen, Catherine A. Read, J. Spiro, Wei-Sen Lam, Anna K. Nowak, Jenette Creaney, Sukanya Arunachalam, Y. C. Gary Lee, Aron Chakera, Jason Charng
Publikováno v:
Clinicalexperimental ophthalmologyREFERENCES. 49(6)
Background To describe ocular adverse events and retinal changes during fibroblast growth factor receptor (FGFR) inhibitor (AZD4547) anticancer therapy. Methods This is a sub-study examining ocular adverse effects from AZD4547 therapy (single-centre,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a9788c8c9865bb4625b6c2d20655bb
https://pubmed.ncbi.nlm.nih.gov/33934469
https://pubmed.ncbi.nlm.nih.gov/33934469